Effect of Hypertonic Solutions on Allergic Rhinitis Patients

Allergic Rhinitis Clinical Trial

— hypertonic  

Official title:

Do Hypertonic Solutions Have an Impact on Nasal Eosinophilia in Allergic Rhinitis Patients?

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02233426
• Other study ID #: NKU-001
• Status: Not yet recruiting
• Phase: N/A
• First received: August 29, 2014
• Last updated: September 3, 2014
• Start date: September 2014
• Est. completion date: October 2014

Study information

• Verified date: September 2014
• Source: Namik Kemal University
• Contact: Zafer Ciftci, Assist. Prof
• Phone: 00905325540605
• Email: zaferciftci[@]yahoo.com
• Is FDA regulated: No
• Health authority: Turkey: Ministry of Health
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to assess the effectivity of using hypertonic nasal solutions alone on the symptom scores and nasal eosinophil levels of allergic rhinitis patients, retrospectively.

Description:

The medical records of the patients who admitted to outpatient clinic of otorhinolaryngology department of a tertiary referral center were retrospectively investigated. The symptom scores and nasal eosinophil levels of the patients were recorded. Patients using hypertonic solutions alone or steroid nasal spray alone were compared.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 1000
• Est. completion date: October 2014
• Est. primary completion date: October 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients with positive Prick's test to at least one allergen and diagnosed as having allergic rhinitis were included

• Patients who used hypertonic nasal solution alone for at least one month were included as sthe study group

• Patients who used nasal steroid spray alone or at least one month were included as sthe study group

Exclusion Criteria:

• Patients with a history of asthma, urticeria, eczama, diabetes mellitus, hypertension, COPD and other systemic diseases were excluded

Study Design

Observational Model: Case Control, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Allergic Rhinitis
• Rhinitis

Locations

Country	Name	City	State
Turkey	Namik Kemal University, Department of Otorhinolaryngology	Tekirdag

Sponsors (1)

Lead Sponsor	Collaborator
Namik Kemal University

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The number of eosinophils in nasal secretions		The number of eosinophils in nasal secretions that was counted before the therapy and after the first month of therapy would be recorded	No
Secondary	Sinonasal Outcome Test (SNOT-22) questionairre scores		SNOT-22 scores obtained before the treatment and after the first month of treatment would be recorded	No